WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of DDDs for 3 years revision

8he DDDs, which will be reviewed at the March 2019 meeting (3 year revision) are listed below.  See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2019.  

 

ATC codeATC level name (INN/generic name)DDDUnitAdm.route
R03BB07umeclidinium bromide55mcgInhal. powder
R03AC19olodaterol5mcgInhal. solution
J01XX11tedizolid0.2gO,P
J02AC05isavuconazole0.2gO,P
N03AX23brivaracetam0.1gO,P
R03DA11doxofylline0.8gO,P
A06AH03naloxegol25mgO
B01AF03edoxaban60mgO
G03XB51mifepristone, combinations0.21)O
G04BX16tiopronin0.8gO
J01XE03furazidin0.3gO
J04AB05rifapentine0.11gO
L04AA32apremilast60mgO
M09AX03ataluren2.8gO
N04BD03safinamide75mgO
N05AX14iloperidone18mgO
N05BA24bentazepam75mgO
N06BX13idebenone0.9gO
V03AE08ferric citrate6gO
R03CC13clenbuterol40mcgO
V03AE05sucroferric oxyhydroxide1.5gO
V03AX03cobicistat0.15gO
A16AB12elosulfase alfa20mgP
A16AB14sebelipase alfa5mgP
B01AC25cangrelor50mgP
B01AX01defibrotide1.75gP
C10AX13evolocumab10mgP
C10AX14alirocumab5.4mgP
J01DI54ceftolozone and beta-lactamase inhibitor3 2)P
J01XA04dalbavancin1.53)P
J02AC04posaconazole0.3gP
L04AC10secukinumab10mgP
M01AE01ibuprofen1.2gP
R03DX09mepolizumab3.6mgP
1) Refers to mifepristone
2) Refers to ceftolozane
3) Course dose

Last updated: 2018-10-11